Stocksigma LogoStocksigma Logo

Curis Lifesciences Schedules Board Meeting for H1 FY27 Results and IPO Proceeds Review

Curis Lifesciences Limited has scheduled its Board of Directors meeting on 11th Nov'26 to consider and approve the unaudited standalone and consolidated

Curis Lifesciences Schedules Board Meeting for H1 FY27 Results and IPO Proceeds Review

Curis Lifesciences Ltd 路 Intimation 路 11 Nov 2026, 5:30 am

Curis Lifesciences Schedules Board Meeting for H1 FY27 Results and IPO Proceeds Review Curis Lifesciences Limited has scheduled its Board of Directors meeting on 11th Nov'26 to consider and approve the unaudited standalone and consolidated financial results for the half year ended 30th Sep'26. The board will also review the utilization report of Initial Public Offering proceeds and evaluate any statements of deviation or variation under SEBI LODR Regulation 32. In accordance with insider trading regulations, the trading window for designated persons remains closed from 1st Oct'26 until 48 hours post-result declaration.

Original exchange filing (PDF)

More announcements from Curis Lifesciences Ltd

All Curis Lifesciences Ltd announcements